Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?

[1]  O. Hes,et al.  Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. , 2017, Anticancer research.

[2]  H. Duffau,et al.  Epidemiology for primary brain tumors: a nationwide population-based study , 2017, Journal of Neuro-Oncology.

[3]  H. Duffau,et al.  Erratum to: Epidemiology for primary brain tumors: a nationwide population-based study , 2016, Journal of Neuro-Oncology.

[4]  Rostyslav V Bubnov,et al.  Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016 , 2016, EPMA Journal.

[5]  B. Manohar.  Last Frontier , 2016, Journal of Indian Society of Periodontology.

[6]  V. Venur,et al.  Targeted Therapies for Brain Metastases from Breast Cancer , 2016, International journal of molecular sciences.

[7]  W. Kuhn,et al.  Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures , 2016, Tumor Biology.

[8]  U. Demirci,et al.  Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. , 2016, Breast.

[9]  M. Toborek,et al.  Blood-brain Barrier Remodeling during Brain Metastasis Formation , 2016, Molecular medicine.

[10]  Rostyslav V Bubnov,et al.  Flammer syndrome and potential formation of pre-metastatic niches : a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease , 2016 .

[11]  L. Miller,et al.  EGFR and HER2 signaling in breast cancer brain metastasis. , 2016, Frontiers in bioscience.

[12]  Klaus Pantel,et al.  Breast cancer brain metastases: biology and new clinical perspectives , 2016, Breast Cancer Research.

[13]  B. Leone,et al.  Breast cancer brain metastases: the last frontier , 2015, Experimental Hematology & Oncology.

[14]  F. Janku,et al.  Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? , 2015, Expert review of molecular diagnostics.

[15]  Charles M Perou,et al.  αB-crystallin expression in breast cancer is associated with brain metastasis , 2015, npj Breast Cancer.

[16]  A. Kwong,et al.  Identifying risk factors for brain metastasis in breast cancer patients: Implication for a vigorous surveillance program. , 2015, Asian journal of surgery.

[17]  S. Vanharanta.  A hypoxic ticket to the bone metastatic niche , 2015, Breast Cancer Research.

[18]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[19]  Hong Zhao,et al.  CXCR4 in breast cancer: oncogenic role and therapeutic targeting , 2015, Drug design, development and therapy.

[20]  R. Linding,et al.  The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase , 2015, Nature.

[21]  Jeffrey S. Weinberg,et al.  Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Z. Ren,et al.  Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.

[23]  S. Margolin,et al.  CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Makki,et al.  Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance , 2015, Clinical medicine insights. Pathology.

[25]  Bahrami Tayyeb,et al.  Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network , 2014, Molecular Neurobiology.

[26]  M. Gnant,et al.  Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. , 2014, Breast.

[27]  R. Jandial,et al.  Role of the neural niche in brain metastatic cancer. , 2014, Cancer research.

[28]  C. Anders,et al.  Breast cancer brain metastases: evidence for neuronal-like adaptation in a ‘breast-to-brain’ transition? , 2014, Breast Cancer Research.

[29]  O. Topolcan,et al.  New treatment paradigm for patients with anaplastic oligodendroglial tumors. , 2014, Anticancer research.

[30]  J. Baselga,et al.  Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Chun-Yu Liu,et al.  Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients , 2014, PloS one.

[32]  H. Nakshatri,et al.  Angiopoietin‐2 mediates blood–brain barrier impairment and colonization of triple‐negative breast cancer cells in brain , 2014, The Journal of pathology.

[33]  E. Petricoin,et al.  Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis , 2014, PloS one.

[34]  P. Brastianos,et al.  Human breast cancer metastases to the brain display GABAergic properties in the neural niche , 2014 .

[35]  J. Jassem,et al.  Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. , 2013, Breast.

[36]  C. Miller,et al.  αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain , 2013, Clinical Cancer Research.

[37]  Erin M. Olson,et al.  Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[39]  R. Gelber,et al.  CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). , 2013, The Lancet. Oncology.

[40]  R. Jandial,et al.  Co-evolution of breast-to-brain metastasis and neural progenitor cells , 2013, Clinical & Experimental Metastasis.

[41]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[42]  A. Ghia.  Predicting survival in women with breast cancer and brain metastasis: A nomogram outperforms current survival prediction models , 2013 .

[43]  Toshiyuki Shimada,et al.  Retrospective Analysis of Risk Factors for Central Nervous System Metastases in Operable Breast Cancer: Effects of Biologic Subtype and Ki67 Overexpression on Survival , 2012, Oncology.

[44]  Nicholas F. Marko,et al.  Predicting survival in women with breast cancer and brain metastasis , 2012, Cancer.

[45]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[46]  Meihua Wang,et al.  A nomogram for individualized estimation of survival among patients with brain metastasis. , 2012, Neuro-oncology.

[47]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Miller,et al.  Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases , 2011, Breast Cancer Research.

[49]  V. Kataja,et al.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study , 2011, Breast Cancer Research.

[50]  F. Heitz,et al.  Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Charles M. Perou,et al.  Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.

[52]  P. Steeg,et al.  Notch1 Inhibition Alters the CD44hi/CD24lo Population and Reduces the Formation of Brain Metastases from Breast Cancer , 2011, Molecular Cancer Research.

[53]  I. Bechmann,et al.  Microglia promote colonization of brain tissue by breast cancer cells in a Wnt‐dependent way , 2010, Glia.

[54]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Stephen Fox,et al.  HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer , 2010, Breast Cancer Research.

[56]  Roman Rouzier,et al.  Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  F. Heitz,et al.  Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. , 2009, European journal of cancer.

[58]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[59]  A. Vortmeyer,et al.  Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization , 2008, Clinical & Experimental Metastasis.

[60]  Mi Hyun Kim,et al.  Activation of Notch Signaling in a Xenograft Model of Brain Metastasis , 2008, Clinical Cancer Research.

[61]  F. Siannis,et al.  Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. , 2008, The oncologist.

[62]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[63]  M. Milella,et al.  Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.

[64]  G. Viani,et al.  Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.

[65]  N. Lin.  Primary Breast Cancer Phenotypes Associated With Propensity for Central Nervous System Metastases , 2007 .

[66]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.

[67]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[69]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Tae-Hee Lee,et al.  Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. , 2004, Molecular cancer research : MCR.

[71]  Suyun Huang,et al.  Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice , 2004, Clinical & Experimental Metastasis.

[72]  S. Lo,et al.  Diagnosis and management of central nervous system metastases from breast cancer. , 2003, The oncologist.

[73]  Tae-Hee Lee,et al.  Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.

[74]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[75]  O. Topolcan,et al.  Glioblastoma Multiforme – a Review of Pathogenesis , Biomarkers and Therapeutic Perspectives , 2022 .